Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 9/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2819634 | 1.00 | LMNA (0.47) | LMNASMN1; SMN2ALDH1A1TBXA2RL3MBTL1 | |
| SCHEMBL2820423 | 0.94 | LMNA (0.52) | LMNASMN1; SMN2ALDH1A1TBXA2RL3MBTL1 | |
| SCHEMBL3829845 | 0.90 | LMNA (0.45) | LMNASMN1; SMN2ALDH1A1TBXA2RL3MBTL1 | |
| SCHEMBL2820262 | 0.82 | L3MBTL1 (0.52) | LMNASMN1; SMN2ALDH1A1TBXA2RL3MBTL1 | |
| SCHEMBL2820085 | 0.81 | ALDH1A1 (0.56) | LMNASMN1; SMN2ALDH1A1TBXA2RL3MBTL1 | |
| SCHEMBL2820039 | 0.80 | LMNA (0.46) | LMNASMN1; SMN2ALDH1A1TBXA2RL3MBTL1 | |
| SCHEMBL2819893 | 0.80 | L3MBTL1 (0.51) | LMNASMN1; SMN2ALDH1A1TBXA2RL3MBTL1 | |
| SCHEMBL2821135 | 0.80 | ALDH1A1 (0.47) | LMNASMN1; SMN2ALDH1A1TBXA2RL3MBTL1 | |
| SCHEMBL2821983 | 0.80 | L3MBTL1 (0.49) | LMNASMN1; SMN2ALDH1A1TBXA2RL3MBTL1 | |
| Hydrochloric Acid SCHEMBL3014573 | 0.79 | L3MBTL1 (0.50) | LMNASMN1; SMN2ALDH1A1TBXA2RL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1849469-B1 | Arylsulfonamide derivatives for use as CCR3 antagonists in the treatment of inflammatory and immunological disorders | AXIKIN PHARMACEUTICALS INC (US) | 2010-10-27 | — | — | EP | claimed |
| US-20100204213-A1 | ARYLSULFONAMIDE DERIVATIVES FOR USE AS CCR3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS | BAYER HEALTHCARE AG (DE) | 2010-08-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204213-A1 | ARYLSULFONAMIDE DERIVATIVES FOR USE AS CCR3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISORDERS | CCR3, CCR1, CCR2 | LMNA 4588/4885SMN1; SMN2 2924/4885ALDH1A1 2416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.